NEW YORK (GenomeWeb News) – OncoMethylome Sciences has inked a worldwide non-exclusive agreement granting Qiagen rights to use certain of its methylation technologies in future Qiagen products, the Liege, Belgium-based firm said today.
 
The firms anticipate that these future products will expand, among others, Qiagen’s EpiTect product line. Specifically, the agreement covers OncoMethylome Sciences’ methylation-specific PCR technology.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

This year's Breakthrough Prize winners include a pair that developed a therapy for spinal muscular atrophy.

The New York Times reports on how white supremacists misconstrue genetic research, concerning many geneticists.

Researchers find that people's genetics influence their success at university, but that it is not the only factor.

In Nature this week: approach to identify genetic variants that affect trait variability, application of read clouds to microbiome samples, and more.